ADPT (Adaptive Biotechnologies) Occupancy Rate %: 0.00% (As of Mar. 2026)


ADPT Adaptive Biotechnologies Corp ADPT
68 GF Score
Price $21.06
GF Value $10.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Occupancy Rate %?

Adaptive Biotechnologies ADPT -3.39% 68 Occupancy Rate % is 0.00% as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 68/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Occupancy Rate % shows the actual utilization of an inpatient health facility for a given time period.

The historical rank and industry rank for Adaptive Biotechnologies's Occupancy Rate % or its related term are showing as below:

ADPT's Occupancy Rate % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Occupancy Rate % only.

Adaptive Biotechnologies  (NAS:ADPT) Occupancy Rate % Explanation

Occupancy Rate % is a calculation used to show the actual utilization of an inpatient health facility for a given time period. The occupancy rate reflects the degree to which hospital beds have been utilized even though the number of beds may have changed during the reporting period.

The average occupancy rate of community (that is, non-Federal, short-term general) hospitals is about 76%. We can recognize a hospital with a too-low occupancy rate as inefficient; such a hospital may find it hard to meet its profit goals. However, a constantly high occupancy rate may not be a good sign, either. Very high occupancy rates may reflect that the hospital is under great pressure from medical and labor sources. Thus, a reasonable occupancy rate is more acceptable than a high one.


Adaptive Biotechnologies Occupancy Rate % Related Terms


Adaptive Biotechnologies Occupancy Rate % Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Occupancy Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Occupancy Rate % Chart

Adaptive Biotechnologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Occupancy Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only

Adaptive BiotechnologiesQuarterly Data
Trend Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Occupancy Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only

ADPT vs GRAL, WGS, RDNT: Occupancy Rate % Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Occupancy Rate %, along with its competitors' market caps and Occupancy Rate % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADPT
68GF Score
Adaptive Biotechnologies Corp ADPT
Occupancy Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies  (NAS:ADPT) Occupancy Rate % Calculation

To calculate Occupancy Rate %, we use inpatient days of care and bed days available. Inpatient days of care is the sum of each daily inpatient census for the year. Bed days available is the maximum number of inpatient days of care that would have been provided if all beds were filled during the year. The formula is:

Occupancy Rate %=( Inpatient Days of Care / Bed Days Available ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions
What does a Occupancy Rate % of 0.00% mean?
Adaptive Biotechnologies (ADPT) has a Occupancy Rate % of 0.00% as of Mar. 2026. Occupancy Rate shows the actual utilization of an inpatient health facility for a given time period. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Occupancy Rate % too high?
Adaptive Biotechnologies' current Occupancy Rate % is 0.00%. Overall, Adaptive Biotechnologies has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Occupancy Rate % compare to GRAL and WGS?
Adaptive Biotechnologies' Occupancy Rate % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Occupancy Rate % for a Medical Diagnostics & Research company?
A good Occupancy Rate % depends on the Medical Diagnostics & Research industry context. However, Occupancy Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Occupancy Rate % mean?
A high Occupancy Rate % can signal that a stock is expensive relative to its fundamentals. Occupancy Rate shows the actual utilization of an inpatient health facility for a given time period. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Occupancy Rate % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $21.06 — trading 109.6% above its estimated fair value. The current Occupancy Rate % is 0.00%. Adaptive Biotechnologies' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Occupancy Rate % calculated?
Occupancy Rate % is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Occupancy Rate % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.06 is trading 109.6% above its estimated GF Value™ of $10.05. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Occupancy Rate %: 0.00%
  • GF Value™: $10.05 vs. price of $21.06 (109.6% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score

Get the complete analysis for ADPT

Occupancy Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.06
Price
$10.05
GF Value